Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Results- Audited Financial Results For The Quarter And Year Ended March 31, 2022

 In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at its Meeting held today i.e. Friday, May 20, 2022, inter alia, considered and approved the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022 along with the Auditors Report. We are enclosing herewith copies of: i. Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022 ii. Auditor's Report issued by M/s. Mittal Agarwal & Co., Chartered Accountants (FRN - 131025W), Statutory Auditors of the Company for the Financial Year ended March 31, 2022 iii. Declaration on Auditors Report with unmodified opinion on the Audited Financial Results of the Company for the Financial Year ended March 31, 2022. iv. Investor Presentation.
20-05-2022
Bigul

Annual report for Gufic BioSciences Ltd. for FY-2022
20-05-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company will host an Earnings Conference Call (Virtual) for Investors/Analysts on Monday, May 23, 2022, at 16:30 hours (IST), during which officials of the Company will discuss the business background/prospects and financial performance of the Company and take questions. The details of the Earnings Conference call are mentioned in the Call Invite enclosed herewith. Kindly take the same on record.
17-05-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Corporate Action-Board to consider Dividend

 Pursuant to the provisions of Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 20, 2022, inter alia, to consider the following business matters: 1. To approve the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022. 2. To consider and recommend dividend, if any, for the Financial Year 2021-22, subject to approval of shareholders at their ensuing Annual General Meeting
13-05-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Intimation for Audited Financial Results And Recommendation Of Final Dividend, If Any.

 GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022 and recommend final dividend, if any, for the Financial Year 2021-22, subject to approval of shareholders at their ensuing Annual General Meeting.
13-05-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements Regulations), 2015 and as per information received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company, the information regarding loss of Share Certificate received from the shareholder of the Company is uploaded.
13-05-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Compliances- Submission Of Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to the provisions of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith certificate received from M/s. Manish Ghia & Associates, Practicing Company Secretary, Mumbai for the year ended March 31, 2022. Kindly take the same on your record.
27-04-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGUFIC BIOSCIENCES LTD. 2CINL24100MH1984PLC033519 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 55.09 4Highest Credit Rating during the previous FY BBB+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ami N Shah Designation: Company Secretary and Compliance Officer EmailId: mgr_legal@guficbio.com Name of the Chief Financial Officer: Devkinandan B Roonghta Designation: Chief Financial Officer EmailId: roonghta@guficbio.com Date: 26/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
26-04-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Outcome for Outcome Of The Board Meeting

 Pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Regulations'), we would like to inform that the Board of Directors at their meeting held on April 19, 2022 i.e., today, inter alia approved the following agenda item: Signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of 1,307,000 fully paid ordinary equity shares in Selvax aggregating to 2.67% of its total paid up share capital for a subscription fee of around USD 0.07651 per equity share aggregating to USD 100,000/- Kindly note that the Company have also entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment. Kindly take the same on your record.
19-04-2022
Bigul

GUFIC BIOSCIENCES LTD. - 509079 - Compliances - Compliance Certificate For The Period Ended March 31, 2022

 As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facilities are maintained during the period April 01, 2021 to March 31, 2022 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058.
13-04-2022
Next Page
Close

Let's Open Free Demat Account